deltatrials
Active Not Recruiting INTERVENTIONAL NCT05071846

MVX-ONCO-2 in Advanced Solid Tumors

An Open Label, Single Arm, Phase I Clinical Study Assessing Safety, Tolerability, and Efficacy of MVX-ONCO-2 in Patients With Advanced Solid Tumors

Sponsor: University Hospital, Geneva

Conditions Solid Tumor, Adult
Interventions MVX-ONCO-2
Updated 9 times since 2021 Last updated: Apr 8, 2026 Started: Oct 22, 2024 Primary completion: Nov 1, 2026 Completion: Oct 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Solid Tumor, Adult, this trial is ongoing. The trial is conducted by University Hospital, Geneva and has accumulated 9 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshotNot Yet Recruiting~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshotWithdrawn~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~May 2025 · 6 months · monthly snapshotRecruiting~May 2025 – ~Apr 2026 · 11 months · monthly snapshotRecruitingApr 16, 2026 – present · 4 months · daily API

Change History

9 versions recorded

  1. Apr 16, 2026 — Present [daily]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting · Phase: PHASE1 → None

  2. May 2025 — Apr 2026 [monthly]

    Recruiting PHASE1

  3. Nov 2024 — May 2025 [monthly]

    Recruiting PHASE1

    Status: Withdrawn → Recruiting

  4. Sep 2024 — Nov 2024 [monthly]

    Withdrawn PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Withdrawn PHASE1

▶ Show 4 earlier versions

  1. Feb 2023 — Jul 2024 [monthly]

    Withdrawn PHASE1

    Status: Not Yet Recruiting → Withdrawn

  2. Sep 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE1

  3. Feb 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1

  4. Nov 2021 — Feb 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

MVX-ONCO-2 is a patient-specific, cell-based, active immunotherapy where the participant's immune response to their own tumor cells is stimulated and/or increased. MVX-ONCO-2 is composed of a cell suspension of irradiated autologous tumor cells and two capsules loaded with allogenic genetically modified cells releasing an immunomodulator, granulocyte-macrophage colony stimulating factor (GM-CSF). MVX-ONCO-2 is an evolution of MVX-ONCO-1, which was approved for clinical investigation under the same category in a phase I and a phase II clinical trials. The objectives of the trial are to investigate the safety, tolerability and signals of efficacy of MVX-ONCO-2 in participants with advanced solid tumors.

Contact Information

Sponsor contact:
  • University Hospital, Geneva
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations